Ovid Therapeutics (OVID) Common Equity (2016 - 2026)

Ovid Therapeutics' Common Equity history runs 11 years deep, the most recent figure standing at $198.3 million for Q1 2026.

• Quarterly Common Equity rose 234.48% year-over-year to $198.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.3 million (up 234.48% YoY) and the FY2025 annual result came in at $130.7 million, up 91.51% from the prior year.
• Common Equity was $198.3 million for Q1 2026 at Ovid Therapeutics, up from $130.7 million in the prior quarter.
• Across five years, Common Equity topped out at $198.3 million in Q1 2026 and bottomed at $44.7 million in Q3 2025.
• A 5-year average of $106.6 million and a median of $101.3 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity tumbled 41.41% — and 2026, when it surged 234.48%.
• Ovid Therapeutics' Common Equity stood at $132.3 million in 2022, then sank by 33.62% to $87.8 million in 2023, then slipped by 22.29% to $68.2 million in 2024, then soared by 91.51% to $130.7 million in 2025, then soared by 51.74% to $198.3 million in 2026.
• Business Quant data shows OVID's Common Equity at $198.3 million in Q1 2026, $130.7 million in Q4 2025, and $44.7 million in Q3 2025.